Fuller H B Co (FUL) Stock Analysis and Metrics

Fuller H B

NYSE: FUL

$55.65 ▲ +0.53 (+0.96%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap3.04 Bn

P/E21.53

P/S0.87

Div. Yield0.02

Total Debt (Qtr)2.07 Bn

Revenue Growth (1y) (Qtr)5.81

Add ratio to table…

About

H. B. Fuller Company is a leading worldwide formulator, manufacturer and marketer of adhesives, sealants and other specialty chemical products. Sales operations span 34 countries across North America, Europe, Latin America, Asia Pacific, India, the Middle East and Africa. The company's core product offering is industrial adhesives that help improve product performance or manufacturing processes for customers.

The company generates revenue by selling its adhesives, sealants and specialty chemical products to manufacturers in industries such as food and beverage, hygiene, consumer goods, automotive, aerospace, electronics, construction and industrial sectors. In addition, it provides technical support and customized solutions to address specific customer needs.

The company operates through the following segments.

• Hygiene, Health and Consumable Adhesives: This segment provides adhesives for hygiene products, health care items and consumer goods such as diapers, medical devices, food packaging and personal care items.

• Engineering Adhesives: This segment supplies adhesives for industrial applications including automotive, aerospace, electronics, appliances and durable goods assembly.

• Construction Adhesives: This segment offers adhesives and sealants for construction markets including roofing, flooring, insulation, windows, doors and infrastructure projects.

• Building Adhesive Solutions: This segment combines insulating glass, woodworking, composite, roofing and building envelope adhesives to serve residential, commercial and industrial construction needs.

H. B. Fuller Company holds a strong position in the global adhesives market due to its broad product portfolio, extensive geographic reach and technical service capabilities. It competes with multinational suppliers such as Henkel, 3M and Arkema as well as numerous regional specialty firms. Competitive advantages include product innovation, supply reliability and long term customer relationships.

The company serves a diverse customer base that includes manufacturers of food and beverages, hygiene products, clothing, major appliances, electronics, automobiles, aerospace and defense products, solar energy systems, filters, construction materials, roofing systems, furniture, cabinetry, windows, doors, tissue and towel, corrugation, tube winding, packaging and tapes and labels. No single customer accounts for more than 10% of consolidated net revenue.

Investment Thesis

▲ Bull case

The Middle East supply chain disruption is creating a structural advantage for H.B. Fuller that the market is underpricing. Management’s aggressive securing of raw materials through long‑term contracts and strategic reallocation across regions positions the company to capture market share when competitors face genuine shortages. This ability to lock in supply not only mitigates immediate cost pressures but also builds durable relationships with suppliers that can be leveraged for preferential pricing in future periods. The resulting pricing power, evidenced by the early 10% global price increase and the willingness to go higher on specific technologies, translates into margin expansion that exceeds the low‑single‑digit organic growth guidance. Over time, as the supply chain rebalances, Fuller’s entrenched supplier network will allow it to maintain higher prices while competitors scramble for allocations, creating a sustainable tailwind to earnings. The market’s focus on the near‑term volume decline overlooks this shift from a cost‑pass‑through environment to a share‑gain environment driven by supply security.
Project Quantum Leap and the newly announced Aerospace Manufacturing Center of Excellence are catalysts that will unlock higher‑margin growth streams that are not fully reflected in current valuations. Quantum Leap’s ongoing plant redesign and supply‑chain optimization are already delivering incremental EBITDA benefits, with management indicating an increased cost‑savings target of $15 million for the year. The Aerospace Center, slated to open in early 2027, will consolidate high‑value, high‑margin aerospace adhesive production under one roof, enabling the capture of long‑term qualification contracts and reducing per‑unit costs through economies of scale. These initiatives align with the company’s strategy to shift the portfolio toward faster‑growing, higher‑margin specialty segments such as electronics, aerospace, and advanced barrier coatings. The market’s current pricing assumes only modest incremental benefits from these projects, underestimating the potential for double‑digit EBITDA margin expansion as the assets come online.
The VerdaFresh oxygen‑barrier technology represents a hidden growth driver in the Hygiene, Health and Consumables (HHC) segment that could counteract the perceived weakness in that business. By eliminating the need for EVOH and other non‑recyclable layers, VerdaFresh enables mono‑material packaging that meets tightening regulatory and consumer sustainability demands while reducing material costs for customers. This dual benefit of environmental compliance and cost efficiency creates a compelling value proposition that can drive adoption across food, beverage, and personal‑care packaging markets. Management highlighted that the technology expands an already robust barrier‑coating portfolio, positioning Fuller to lead the transition toward circular, high‑margin packaging solutions. The market’s focus on HHC’s volume decline ignores the potential for VerdaFresh to stimulate new demand streams and improve product mix, thereby supporting both top‑line growth and margin expansion in a segment currently viewed as challenged.
Medical adhesives, particularly the fast‑growing European medical business, offer a high‑margin, low‑volatility pocket of growth that is underappreciated. The medical segment reported nearly 20% organic growth in Europe during the quarter, driven by specialty cyanoacrylate applications that are less sensitive to crude‑oil price fluctuations because the raw material base is dominated by cyanoacetates. This insulation from commodity volatility provides a stable earnings contributor that can offset cyclical weakness in industrial adhesives. Furthermore, the medical business’s small size relative to the overall company means that incremental gains can have an outsized impact on segment margins without requiring massive capital investment. The market’s broad‑based view of Fuller as a commodity‑exposed adhesives player overlooks this defensive, high‑growth pocket that could deliver consistent EBITDA accretion.
Capital allocation discipline, including deleveraging and a shift toward share repurchases, is creating a financial flexibility that the market is not fully pricing in. The net‑debt‑to‑adjusted‑EBITDA ratio has improved to 3.1×, down from 3.5× a year ago, and management has signaled a willingness to pause near‑term M&A to focus on deleveraging while returning cash to shareholders. This balance sheet strength reduces financial risk and provides a buffer against potential raw‑material price spikes, allowing the company to maintain its pricing strategy without jeopardizing covenant compliance. Additionally, the increased quarterly dividend signals confidence in sustainable cash flow generation, which can attract income‑focused investors and support the share price. The market’s emphasis on near‑term earnings volatility fails to capture the downside protection and upside optionality embedded in the strengthened balance sheet.

The Middle East supply chain disruption is creating a structural advantage for H.B. Fuller that the market is underpricing. Management’s aggressive securing of raw materials through long‑term contracts and strategic reallocation across regions positions the company to capture market share when competitors face genuine shortages. This ability to lock in supply not only mitigates immediate cost pressures but also builds durable relationships with suppliers that can be leveraged for preferential pricing in future periods. The resulting pricing power, evidenced by the early 10% global price increase and the willingness to go higher on specific technologies, translates into margin expansion that exceeds the low‑single‑digit organic growth guidance. Over time, as the supply chain rebalances, Fuller’s entrenched supplier network will allow it to maintain higher prices while competitors scramble for allocations, creating a sustainable tailwind to earnings. The market’s focus on the near‑term volume decline overlooks this shift from a cost‑pass‑through environment to a share‑gain environment driven by supply security.
Project Quantum Leap and the newly announced Aerospace Manufacturing Center of Excellence are catalysts that will unlock higher‑margin growth streams that are not fully reflected in current valuations. Quantum Leap’s ongoing plant redesign and supply‑chain optimization are already delivering incremental EBITDA benefits, with management indicating an increased cost‑savings target of $15 million for the year. The Aerospace Center, slated to open in early 2027, will consolidate high‑value, high‑margin aerospace adhesive production under one roof, enabling the capture of long‑term qualification contracts and reducing per‑unit costs through economies of scale. These initiatives align with the company’s strategy to shift the portfolio toward faster‑growing, higher‑margin specialty segments such as electronics, aerospace, and advanced barrier coatings. The market’s current pricing assumes only modest incremental benefits from these projects, underestimating the potential for double‑digit EBITDA margin expansion as the assets come online.
The VerdaFresh oxygen‑barrier technology represents a hidden growth driver in the Hygiene, Health and Consumables (HHC) segment that could counteract the perceived weakness in that business. By eliminating the need for EVOH and other non‑recyclable layers, VerdaFresh enables mono‑material packaging that meets tightening regulatory and consumer sustainability demands while reducing material costs for customers. This dual benefit of environmental compliance and cost efficiency creates a compelling value proposition that can drive adoption across food, beverage, and personal‑care packaging markets. Management highlighted that the technology expands an already robust barrier‑coating portfolio, positioning Fuller to lead the transition toward circular, high‑margin packaging solutions. The market’s focus on HHC’s volume decline ignores the potential for VerdaFresh to stimulate new demand streams and improve product mix, thereby supporting both top‑line growth and margin expansion in a segment currently viewed as challenged.
Medical adhesives, particularly the fast‑growing European medical business, offer a high‑margin, low‑volatility pocket of growth that is underappreciated. The medical segment reported nearly 20% organic growth in Europe during the quarter, driven by specialty cyanoacrylate applications that are less sensitive to crude‑oil price fluctuations because the raw material base is dominated by cyanoacetates. This insulation from commodity volatility provides a stable earnings contributor that can offset cyclical weakness in industrial adhesives. Furthermore, the medical business’s small size relative to the overall company means that incremental gains can have an outsized impact on segment margins without requiring massive capital investment. The market’s broad‑based view of Fuller as a commodity‑exposed adhesives player overlooks this defensive, high‑growth pocket that could deliver consistent EBITDA accretion.
Capital allocation discipline, including deleveraging and a shift toward share repurchases, is creating a financial flexibility that the market is not fully pricing in. The net‑debt‑to‑adjusted‑EBITDA ratio has improved to 3.1×, down from 3.5× a year ago, and management has signaled a willingness to pause near‑term M&A to focus on deleveraging while returning cash to shareholders. This balance sheet strength reduces financial risk and provides a buffer against potential raw‑material price spikes, allowing the company to maintain its pricing strategy without jeopardizing covenant compliance. Additionally, the increased quarterly dividend signals confidence in sustainable cash flow generation, which can attract income‑focused investors and support the share price. The market’s emphasis on near‑term earnings volatility fails to capture the downside protection and upside optionality embedded in the strengthened balance sheet.

▼ Bear case

The volume outlook of a 5% decline for the year reflects a genuine risk of demand destruction that the market may be underestimating, especially in the health‑hygiene‑consumables segment where consumers are shifting to lower‑cost, smaller‑package products. This trend reduces adhesive usage per unit sold and is compounded by tighter inventory management at both large customers and distributors, which could persist beyond the current quarter. If affordability pressures remain elevated, the volume headwind could be larger than assumed, eroding the benefits from pricing and market‑share gains. The market’s optimism about gaining share from competitors’ raw‑material shortages may be offset by a broader contraction in end‑market demand, leaving Fuller with higher prices but lower overall sales volume.
Reliance on price increases to offset raw‑material cost inflation carries the risk that the company may not be able to fully pass through higher costs, particularly if suppliers raise prices beyond what customers are willing to absorb. Management noted that some raw‑material classes have experienced spot‑price spikes of up to 300% in Europe, and while caps and negotiated availability have been secured for certain materials, not all inputs are covered. If the inflationary environment intensifies and the company’s pricing power wanes, gross margins could compress despite the current 170‑basis‑point improvement. The market’s assumption that pricing actions will sustainably protect margins may be overly optimistic if the cost base continues to outpace the ability to raise prices.
The proposed acquisition of Advanced Medical Solutions Group (AMS) introduces execution and leverage risks that could undermine the company’s deleveraging progress and create integration challenges. Ancora’s public opposition highlights concerns about entering a fragmented regulatory environment across Europe, which could increase compliance costs and dilute focus on core adhesive operations. If the deal proceeds, the added debt could push the net‑debt‑to‑EBITDA ratio back toward or above historical highs, constraining financial flexibility and potentially triggering covenant pressures. Moreover, the distraction of a large cross‑border acquisition could impede the execution of Quantum Leap and other organic initiatives, slowing the realization of expected synergies. The market’s current pricing may not fully reflect the downside scenario where the AMS deal erodes balance‑sheet strength and diverts management attention.
Project Quantum Leap and the Aerospace Manufacturing Center of Excellence, while promising, entail execution risk that could delay or diminish the anticipated cost savings and margin improvements. Large‑scale plant redesigns and new facility constructions are subject to construction delays, cost overruns, and technology‑integration challenges. If the Quantum Leap savings fall short of the revised $15 million target or the Aerospace Center encounters certification delays, the expected EBITDA uplift may not materialize on the timeline implied by management. The market’s bullish case assumes smooth execution; any setbacks would directly impact profitability and could lead to disappointing results relative to guidance.
The VerdaFresh barrier‑coating technology, although innovative, faces adoption risk that could limit its contribution to growth. Success depends on customers’ willingness to redesign packaging lines, qualify new mono‑material structures, and potentially incur up‑front tooling costs. If regulatory timelines for recyclable packaging extend beyond expectations or if competing sustainable solutions gain traction faster, VerdaFresh may achieve slower-than‑anticipated market penetration. The market’s optimism about this technology offsetting HHC weakness assumes a rapid uptake that may not materialize, leaving the segment vulnerable to continued volume pressure and mix shift.

The volume outlook of a 5% decline for the year reflects a genuine risk of demand destruction that the market may be underestimating, especially in the health‑hygiene‑consumables segment where consumers are shifting to lower‑cost, smaller‑package products. This trend reduces adhesive usage per unit sold and is compounded by tighter inventory management at both large customers and distributors, which could persist beyond the current quarter. If affordability pressures remain elevated, the volume headwind could be larger than assumed, eroding the benefits from pricing and market‑share gains. The market’s optimism about gaining share from competitors’ raw‑material shortages may be offset by a broader contraction in end‑market demand, leaving Fuller with higher prices but lower overall sales volume.
Reliance on price increases to offset raw‑material cost inflation carries the risk that the company may not be able to fully pass through higher costs, particularly if suppliers raise prices beyond what customers are willing to absorb. Management noted that some raw‑material classes have experienced spot‑price spikes of up to 300% in Europe, and while caps and negotiated availability have been secured for certain materials, not all inputs are covered. If the inflationary environment intensifies and the company’s pricing power wanes, gross margins could compress despite the current 170‑basis‑point improvement. The market’s assumption that pricing actions will sustainably protect margins may be overly optimistic if the cost base continues to outpace the ability to raise prices.
The proposed acquisition of Advanced Medical Solutions Group (AMS) introduces execution and leverage risks that could undermine the company’s deleveraging progress and create integration challenges. Ancora’s public opposition highlights concerns about entering a fragmented regulatory environment across Europe, which could increase compliance costs and dilute focus on core adhesive operations. If the deal proceeds, the added debt could push the net‑debt‑to‑EBITDA ratio back toward or above historical highs, constraining financial flexibility and potentially triggering covenant pressures. Moreover, the distraction of a large cross‑border acquisition could impede the execution of Quantum Leap and other organic initiatives, slowing the realization of expected synergies. The market’s current pricing may not fully reflect the downside scenario where the AMS deal erodes balance‑sheet strength and diverts management attention.
Project Quantum Leap and the Aerospace Manufacturing Center of Excellence, while promising, entail execution risk that could delay or diminish the anticipated cost savings and margin improvements. Large‑scale plant redesigns and new facility constructions are subject to construction delays, cost overruns, and technology‑integration challenges. If the Quantum Leap savings fall short of the revised $15 million target or the Aerospace Center encounters certification delays, the expected EBITDA uplift may not materialize on the timeline implied by management. The market’s bullish case assumes smooth execution; any setbacks would directly impact profitability and could lead to disappointing results relative to guidance.
The VerdaFresh barrier‑coating technology, although innovative, faces adoption risk that could limit its contribution to growth. Success depends on customers’ willingness to redesign packaging lines, qualify new mono‑material structures, and potentially incur up‑front tooling costs. If regulatory timelines for recyclable packaging extend beyond expectations or if competing sustainable solutions gain traction faster, VerdaFresh may achieve slower-than‑anticipated market penetration. The market’s optimism about this technology offsetting HHC weakness assumes a rapid uptake that may not materialize, leaving the segment vulnerable to continued volume pressure and mix shift.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Specialty Chemicals

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LIN	Linde Plc	237.95 Bn	33.52	6.87	24.68 Bn
2	SHW	Sherwin Williams Co	78.17 Bn	30.07	3.27	11.70 Bn
3	ECL	Ecolab Inc.	76.02 Bn	30.01	4.73	8.24 Bn
4	APD	Air Products & Chemicals, Inc.	66.38 Bn	47.14	5.33	17.40 Bn
5	PPG	Ppg Industries Inc	26.02 Bn	3,717.41	1.61	7.83 Bn
6	LYB	LyondellBasell Industries N.V.	22.51 Bn	-28.53	0.76	11.45 Bn
7	SQM	Chemical & Mining Co Of Chile Inc	19.70 Bn	21.77	3.72	4.79 Bn
8	IFF	International Flavors & Fragrances Inc	19.51 Bn	-102.16	1.81	5.82 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password